The 2nd Edition of SLAS advanced 3D human models and High-Content Analysis Conference was a great event with interesting presentations and posters from public labs and various companies.
In regards of the different presentations, it seems obvious that developing 3D cell culture models is essential to find new leads relevant with in vivo models. Working with 3D models mimicking the ExtraCellular Matrix and with co-culture models opens the door for new druggrable opportunities that could not be identified in a simple 2D model. Facing more complex models, with downstream process in ‘OMICS’ analysis, and generating high content imaging, the Artificial Intelligence helps to validate relevant in vitro 3D models that is the first step for ”in vitro clinical assays” with patient’s IPS cells.
Microfluidic systems, by enabling full differentiation of iPSC and mimicking vascularization, seems also inevitable to asset drug efficacy & safety in long term culture.
— SLAS (@SLAS_Org) October 18, 2018
A good example of a successful combination of these technologies is the intestinal model of Pr Matthias Lutolf’s team (Laboratory of stem cell bioengineering, Ecole Polytechnique Fédérale de Lausanne). Extracellular matrix components enhance long term cell survival and differentiation of murine intestinal crypts cells (Gjorevski et al 2016. Nature 539:7630, 560-560). Incorporated in a structured microfluidic systems, this model allows reconstitution of an intestinal tube with crypts and stem cell niches.
In HCS Pharma, we will be happy to discuss with you about your specific needs to find the right customized model 3D model, in co-culture, using IPS or primary cells. Our BIOMIMESYS® technology (https://biomimesys.com/) could be adapted to each cell type in terms of composition (ECM composition) and physical properties (elastic modulus). We could also partner with you about Artificial Intelligence program, to help you in your data management for images analysis. Contact us on this page or at email@example.com!